PUBLIC COMPANY
saveAMO Pharma Ltd
founded 2015 · Leeds, England, GBupdated 2mo ago
AMO Pharma is a privately held clinical-stage biopharmaceutical company developing therapies for rare genetic neurodevelopmental and neuromuscular disorders. Its lead asset is AMO-02 (tideglusib), a GSK-3 inhibitor in development for congenital and childhood-onset myotonic dystrophy type 1, alongside additional programs in Phelan-McDermid and Rett syndromes.
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
- phase2Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
- —Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy
- phase3Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that